PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Contact:
NCT Number:
Protocol:
AAAS2588
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
This study will look at the safety of a drug (REGN5458) in patients with multiple myeloma. It will also try to find out what the best dose of REGN5458 is and look for any signs that REGN5458 can help treat your cancer. REGN5458 is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) for any condition.
Are you Eligible? (Inclusion Criteria)
- Are you at least 18 years old?
- Have you been diagnosed with Multiple Myeloma?
- Has your disease progressed?
Specialty Area(s)
Multiple Myeloma/Amyloidosis
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
